
Leads, develops, and mentors the Innovation Science team, ensuring strong scientific capability and high performance.
Defines scientific strategy for early‑feasibility assessments in alignment with R&D Enteral Nutrition priorities.
Leads the design and development of complex formulations for clinical nutrition products and target delivery systems including scale‑up feasibility. Oversees analytical method development for early innovation and development projects.
Leads process development and process optimization for pharmaceutical and non‑pharmaceutical products, including feasibility of new technologies and proof of concept studies (in-vitro digestion).
Generates scientific knowledge on production processes, ingredient interactions, analytical approaches and emerging technologies.
Drives innovation development including generation of new product ideas and concepts, design of feasibility projects as well as proactive seeking for opportunities to enhance current methods.
Provides strategic scientific recommendations to guide early go/no‑go decisions within innovation pipelines.
Provides early experimental evidence and technology insights that support IP generation. Provide scientific statements for IP or support patent oppositions experimentally
Represents Innovation Science towards internal stakeholders (BU Nutrition, Regulatory, IP, Quality, Production, Clinical, Procurement).
Collaborate closely mainly but not exclusively with R&D Enteral Nutrition, Portfolio Management, Medical Scientific and Clinical Affairs, Intellectual Property, Regulatory Affairs, Quality and external partners, supporting cross‑departmental alignment to ensure smooth transition of innovation projects into formal development phases.
Ensure scientific integrity, reproducibility and compliance in all innovation activities.
Owns the Innovation Science cost center, define annual budgets and ensure efficient use of resources (equipment, consumables, personnel).
Decide on acquisition and implementation of complex equipment and software

As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies.
In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care.
Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare.
Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale.
User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions
Imprint: www.fresenius-kabi.com/imprint